INGENITO GARY 4

4 · CATALYST PHARMACEUTICALS, INC. · Filed Mar 7, 2025

Form 4

Period: 2025-03-05

Chief Med. & Reg. Officer

Transactions

Sale
Common stock, par value $0.001 per share
2025-03-05$22.09/sh−44,904$991,929→ 68,873 total
Exercise/Conversion
Options to purchase common stock
2025-03-05−44,904→ 970,378 total
Exercise: $2.24Exp: 2025-12-19→ Common Stock (44,904 underlying)
Exercise/Conversion
Common stock, par value $0.001 per share
2025-03-05$2.24/sh+44,904$100,585→ 113,777 total
Sale
Common stock, par value $0.001 per share
2025-03-06$21.67/sh−180,096$3,902,680→ 68,873 total
Exercise/Conversion
Options to purchase common stock
2025-03-06−180,096→ 790,282 total
Exercise: $2.24Exp: 2025-12-19→ Common Stock (180,096 underlying)
Exercise/Conversion
Common stock, par value $0.001 per share
2025-03-06$2.24/sh+180,096$403,415→ 248,969 total

Footnotes (4)

[F1]Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
[F2]Represents a weighted average price for the shares sold. Shares were sold in a range between $22.00 and $22.285 per share.
[F3]Represents a weighted average price for the shares sold. Shares were sold in a range between $21.60 and $21.95 per share.
[F4]Options vested in three annual tranches beginning on December 19, 2019.

Documents

1 file